No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MOR240517C17500
- 0.45
- -0.15-25.00%
15min DelayClose May 10 15:59 ET
0.45High0.45Low
0.45Open0.60Pre Close1 Volume49 Open Interest17.50Strike Price45.00Turnover0.00%IV-0.14%PremiumMay 17, 2024Expiry Date0.50Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma37.89Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
MorphoSys (ETR:MOR) Shareholders Have Earned a 228% Return Over the Last Year
MorphoSys AG Announces Major Voting Rights Shift
MorphoSys AG Announces Major Voting Rights Changes
MorphoSys Announces Barclays PLC's Voting Rights Shift
MorphoSys AG Reports Shift in Major Holdings
Analysts' Opinions Are Mixed on These Technology Stocks: Morphosys (GB:0NDV), Thales (GB:0IW5) and Capgemini SE (GB:0HAZ)
Comments
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
5
$MorphoSys(MOR.US$ MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...
1
3
Palantir's Q4 commercial business performance was 'bombastic, baller, incomprehensibly good', according to CEO Alex Karp. Coherent sees 'improving demand trends', expecting 'ongoing sequential improvement in revenue growth'. Chegg's Q1 guidance disappointed investors. NXP Semiconductors' Q4 results surpassed expectations. Novartis' acquisition of MorphoSys is viewed positively.
3
1
3
Read more